Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,deferredLongTermLiab,changeToLiabilities,totalCashflowsFromInvestingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,totalCashFromFinancingActivities,issuanceOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,country,website,maxAge,address1,industry,address2
t0,FRLN,219411000.0,35848300,23265000,,-34936000,,-34945000,10078000,0,-33343000,-33343000,,,,,,9000,0,33343000,0,-1593000,,-34945000,-34945000,16000.0,458857000.0,15820000.0,219427000.0,1449000.0,235247000.0,9377000.0,-250935000.0,11505000.0,1655000.0,195765000.0,15820000.0,11505000.0,10093000.0,223483000.0,16736000.0,5528000.0,,-2581000.0,-2280000.0,288000.0,-34362000.0,2142000.0,-34224000.0,573000.0,98000.0,2343000.0,-2280000.0,,,,207663000.0,en-US,US,EQUITY,True,Delayed Quote,USD,Freeline Therapeutics Holdings ,-0.58870965,143751696,15,America/New_York,EDT,-14400000,False,False,POST,0,4,4.01,1630526402,0.16000032,3.83,4.25,3.8049,549608,NMS,us_market,-0.24938226,1630526707,4.0,-0.010000229,4.155853,3.8049 - 4.25,3.85,3.85,4.18,14,8,finmb_320946407,NasdaqGS,Freeline Therapeutics Holdings plc,USD,412490,261916,1.0900002,0.3732877,2.92 - 18.88,-14.869999,-0.7876059,2.92,18.88,-3.69,-1.086721,4.6790833,-0.6690831,-0.1429945,9.7498045,-5.7398043,,,,18.88,2.92,4.6791,9.7498,412.49k,261.92k,35.85M,,12.37M,8.23%,33.84%,65.25k,1.4,,0.18%,28.3k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-34.28%,-75.28%,,,,,-101.04M,-114.56M,,,195.76M,5.46,,,14.13,,-111.23M,-70.54M,Value,SG1 2FX,Healthcare,236,"Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.",Stevenage,44 14 3890 6870,United Kingdom,http://www.freeline.life,86400,Stevenage Bioscience Catalyst,Biotechnology,Gunnels Wood Road
t-1,FRLN,249777000.0,35848300,19164500,,-31464500,,-31529000,7318500,0,-26483000,-26483000,,,,,,64500,0,26483000,0,-4981500,,-31529000,-31529000,23000.0,456293000.0,18812000.0,249800000.0,501000.0,268612000.0,9008000.0,-215990000.0,9497000.0,1805000.0,229974000.0,18812000.0,9497000.0,8608000.0,258176000.0,16114000.0,8093000.0,,-2988500.0,-918500.0,-850000.0,62087500.0,7736500.0,-32110500.0,525500.0,-45500.0,2777000.0,-981500.0,87380000.0,80879000.0,1513000.0,239364000.0,en-US,US,EQUITY,True,Delayed Quote,USD,Freeline Therapeutics Holdings ,-0.58870965,143751696,15,America/New_York,EDT,-14400000,False,False,POST,0,4,4.01,1630526402,0.16000032,3.83,4.25,3.8049,549608,NMS,us_market,-0.24938226,1630526707,4.0,-0.010000229,4.155853,3.8049 - 4.25,3.85,3.85,4.18,14,8,finmb_320946407,NasdaqGS,Freeline Therapeutics Holdings plc,USD,412490,261916,1.0900002,0.3732877,2.92 - 18.88,-14.869999,-0.7876059,2.92,18.88,-3.69,-1.086721,4.6790833,-0.6690831,-0.1429945,9.7498045,-5.7398043,,,,18.88,2.92,4.6791,9.7498,412.49k,261.92k,35.85M,,12.37M,8.23%,33.84%,65.25k,1.4,,0.18%,28.3k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-34.28%,-75.28%,,,,,-101.04M,-114.56M,,,195.76M,5.46,,,14.13,,-111.23M,-70.54M,Value,SG1 2FX,Healthcare,236,"Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.",Stevenage,44 14 3890 6870,United Kingdom,http://www.freeline.life,86400,Stevenage Bioscience Catalyst,Biotechnology,Gunnels Wood Road
t-2,FRLN,249777000.0,35848300,19164500,,-31464500,,-31529000,7318500,0,-26483000,-26483000,,,,,,64500,0,26483000,0,-4981500,,-31529000,-31529000,23000.0,456293000.0,18812000.0,249800000.0,501000.0,268612000.0,9008000.0,-215990000.0,9497000.0,1805000.0,229974000.0,18812000.0,9497000.0,8608000.0,258176000.0,16114000.0,8093000.0,,-2988500.0,-918500.0,-850000.0,62087500.0,7736500.0,-32110500.0,525500.0,-45500.0,2777000.0,-981500.0,87380000.0,80879000.0,1513000.0,239364000.0,en-US,US,EQUITY,True,Delayed Quote,USD,Freeline Therapeutics Holdings ,-0.58870965,143751696,15,America/New_York,EDT,-14400000,False,False,POST,0,4,4.01,1630526402,0.16000032,3.83,4.25,3.8049,549608,NMS,us_market,-0.24938226,1630526707,4.0,-0.010000229,4.155853,3.8049 - 4.25,3.85,3.85,4.18,14,8,finmb_320946407,NasdaqGS,Freeline Therapeutics Holdings plc,USD,412490,261916,1.0900002,0.3732877,2.92 - 18.88,-14.869999,-0.7876059,2.92,18.88,-3.69,-1.086721,4.6790833,-0.6690831,-0.1429945,9.7498045,-5.7398043,,,,18.88,2.92,4.6791,9.7498,412.49k,261.92k,35.85M,,12.37M,8.23%,33.84%,65.25k,1.4,,0.18%,28.3k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-34.28%,-75.28%,,,,,-101.04M,-114.56M,,,195.76M,5.46,,,14.13,,-111.23M,-70.54M,Value,SG1 2FX,Healthcare,236,"Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.",Stevenage,44 14 3890 6870,United Kingdom,http://www.freeline.life,86400,Stevenage Bioscience Catalyst,Biotechnology,Gunnels Wood Road
t-3,FRLN,84912000.0,35848300,13755000,,-16574000,,-16705000,3735000,0,-17490000,-17490000,,,,,,131000,0,17490000,0,916000,,-16705000,-16705000,32000.0,278923000.0,21483000.0,84955000.0,1264000.0,140463000.0,4312000.0,-152932000.0,-7012000.0,3795000.0,106610000.0,21483000.0,-7012000.0,6755000.0,129881000.0,17032000.0,12862000.0,3000000.0,1528000.0,-561000.0,-3602000.0,-21293000.0,-3961000.0,-17954000.0,495000.0,-45500.0,330000.0,-552000.0,1183000.0,9000.0,-1513000.0,108398000.0,en-US,US,EQUITY,True,Delayed Quote,USD,Freeline Therapeutics Holdings ,-0.58870965,143751696,15,America/New_York,EDT,-14400000,False,False,POST,0,4,4.01,1630526402,0.16000032,3.83,4.25,3.8049,549608,NMS,us_market,-0.24938226,1630526707,4.0,-0.010000229,4.155853,3.8049 - 4.25,3.85,3.85,4.18,14,8,finmb_320946407,NasdaqGS,Freeline Therapeutics Holdings plc,USD,412490,261916,1.0900002,0.3732877,2.92 - 18.88,-14.869999,-0.7876059,2.92,18.88,-3.69,-1.086721,4.6790833,-0.6690831,-0.1429945,9.7498045,-5.7398043,,,,18.88,2.92,4.6791,9.7498,412.49k,261.92k,35.85M,,12.37M,8.23%,33.84%,65.25k,1.4,,0.18%,28.3k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-34.28%,-75.28%,,,,,-101.04M,-114.56M,,,195.76M,5.46,,,14.13,,-111.23M,-70.54M,Value,SG1 2FX,Healthcare,236,"Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.",Stevenage,44 14 3890 6870,United Kingdom,http://www.freeline.life,86400,Stevenage Bioscience Catalyst,Biotechnology,Gunnels Wood Road
